Bio-Reference Laboratories, Inc. Named to BusinessWeek's Latest 100 Top Hot Growth Stocks List.Business Editors/Health/Medical Writers ELMWOOD PARK Elmwood Park, village (1990 pop. 23,206), Cook co., NE Ill., a suburb of Chicago; inc. 1914. It is chiefly residential. , N.J.--(BUSINESS WIRE)--June 1, 2004 Company Ranked # 16 on Annual List Based on Three Year Results in Growth, Earnings Growth and Return on Invested Capital Bio-Reference Laboratories, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRLI BRLI Bio Rad Laboratories Inc ) announced today that BusinessWeek Magazine has named BRLI to its 2004 annual list of the top 100 Hot Growth Stocks, released in the June 7, 2004 issue of the business weekly magazine. Ranking BRLI #16 in the newly released list, the magazine noted "Bio-Reference Laboratories Inc. (BRLI) of Elmwood Park, N.J., has discovered it can capture market share ....by offering an unusual degree of personalized attention and diagnostic prowess in complex and higher-margin areas such as oncology and gene testing gene testing Genetics The evaluation of blood, other body fluids or tissue for biochemical, chromosomal, or genetic markers of genetic disease. See Molecular diagnostics. . It's a field that's expected to expand, thanks to an aging population, increasingly sophisticated technology, and more emphasis on early detection and monitoring of drug treatment." The article quoted Marc Grodman MD, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and President, "We don't live in a world of proprietary technologies....it's how you utilize the technologies and deliver the service." About Bio-Reference Laboratories, Inc. The Company is the largest independent regional clinical laboratory in the Northeast and has major market positions in physician offices, nursing homes and correctional institutions. The Company is a full service clinical laboratory with specialty capability, especially in the areas of genomics, oncology, correctional health, and complimentary medicine. PSIMedica, a business unit of the Company, is a clinical knowledge management (CKM CKM Cabibbo-Kobayashi-Maskawa (quark mixing matrix) CKM Certified Knowledge Manager (trademark of Hudson Associates Consulting, Inc. ) organization offering an array of information solutions for reducing healthcare costs and improving quality performance that are based on a flexible, scalable software analytical engine that utilizes all available source information, including claims data, enrollment data, prescription data and laboratory data. The Company provides a comprehensive connectivity solution to physicians, which includes disease management, laboratory reporting and ordering, as well as claims and eligibility processing through CareEvolve, its web-based healthcare portal. Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements". Statements looking forward in time are included in this release pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to be materially different from any future performance suggested herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion